



SPONTAN[®] prescribed to First Patient Under TGA Special Access Scheme

5 August 2024

Highlights:

- First patients receive SPONTAN[®] under the Therapeutic Goods Administration (TGA) Special Access Scheme
- Demonstrates potential for SPONTAN in an unmet fast-acting, on-demand erectile dysfunction (ED) treatment market
- Internationally recognised Key Opinion Leader (KOL) now actively engaged in prescribing SPONTAN
 - Enables strategic market introduction and collection of real-world data
 - Platform to share experiences at international conferences and scientific publications

LTR Pharma Limited (ASX:LTP) ("LTR Pharma", "the Company"), is pleased to announce that SPONTAN has been prescribed to the first patients under the Therapeutic Goods Administration's ("TGA") Special Access Scheme ("SAS").

Patients were prescribed by the Restorative Sexual Health Clinic (RSHC), which provides evidence-based care to help individuals achieve optimal sexual function and improve intimate relationships. RSHC was founded by Melissa Hadley Barrett, a Nurse Practitioner/Sexologist with extensive experience in primary care. Melissa is a sought-after speaker and educator for health professionals and community members to increase knowledge and education around sexual health and has been published in international peer-reviewed journals.

LTR Pharma Chairman, Lee Rodne said: *"The use of SPONTAN under the early access program marks a watershed moment for LTR Pharma. It demonstrates both the urgent need for fast-acting ED medication and SPONTAN's potential to address a high unmet need for a fast and on-demand ED treatment and allows for hands-on, real-world experience with SPONTAN."*

Key Opinion Leader Involvement

LTR's KOL strategy allows the Company to introduce SPONTAN in a strategic manner through medical leaders in this space. This approach enables LTR to gather real-world data and raise awareness within the medical community, paving the way for broader patient access in the future.

Ms Hadley Barrett's RSHC team uses SPONTAN for select patients who can benefit from a fast-acting nasal spray treatment for ED.

The use of SPONTAN under the SAS program aligns with LTR Pharma's KOL-led methodology for the sustainable introduction of this product to the market. It supports:

- Strategic introduction to the market.
- Collection of real-world data by highly experienced medical professionals.
- Opportunity for KOLs to share experiences at international conferences and in publications.
- Build awareness and knowledge within the wider medical community.



Restorative Sexual Health Clinic's founder, Melissa Hadley Barrett, said, "We see SPONTAN as a valuable addition to our therapeutic capability. SPONTAN complements our holistic approach, offering our patients an innovative option to help address their sexual health concerns and enhance overall well-being."

Special Access Scheme

The TGA's Special Access Scheme enables health practitioners to access unapproved therapeutic goods for individual patients, assessed case-by-case. This milestone marks a pivotal advancement in the Company's strategy to introduce SPONTAN to the market through a meticulously managed, KOL-driven approach. The SAS program facilitates off-market compassionate use of SPONTAN for patients with unmet medical needs, as determined by qualified healthcare professionals.

-Ends-

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is focused on improving men's health, physically and mentally, through the commercialisation of an innovative nasal spray treatment for Erectile Dysfunction. ED is a pressing health issue for millions of men that can negatively impact self-esteem and relationships, across multiple age brackets. LTR Pharma's lead product SPONTAN® is set apart from existing ED therapies by its mechanism of action – intranasal delivery technology of a PDE5 inhibitor. The nasal cavity is a highly vascular part of the body supporting even and rapid absorption of the drug, empowering it to work within 10 minutes or less. LTR Pharma is proudly aiming to restore greater control over the timing, spontaneity, and enjoyment of sexual experiences.

For further information please contact:

Haley Chartres
Media Relations
haley@hck.digital

Peter McLennan
Investor Relations
investors@ltrpharma.com